Hepatocellular Carcinoma
Conditions
Brief summary
The purpose of this study is to evaluate the safety and efficacy of administration of intratumoral IP-001 injection at different dosages (volume and concentration) following local microwave ablation (MWA) or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
Detailed description
This is a Phase 2, five-armed, randomized study designed to evaluate the safety and efficacy of administration of intratumoral IP-001 injection at different dosages (volume and concentration) following local ablation or surgical resection and local ablation in patients with hepatocellular carcinoma who have an intermediate or high risk of recurrence compared to curative ablation or ablation and surgical resection.
Interventions
Participants will receive intratumoral injection of 1.0% IP-001 following local microwave ablation or surgical resection and local microwave ablation
PROCEDURESurgical Resection and Local Ablation
Participants will undergo surgical resection of the tumor and local microwave ablation
PROCEDURELocal Ablation Alone
Participants will have local ablation of the tumor by microwave ablation alone
Sponsors
Robert C. Martin
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years at time of signing Informed Consent. * Has a diagnosis of hepatocellular carcinoma (HCC) documented radiologically by American Association for the Study of Liver Diseases (AASLD) criteria and/or histopathologically from a tumor biopsy. * Has a treatment plan to receive a curative ablation (MWA only) or a curative surgical resection and ablation, or where the patient may benefit from surgery and ablation or ablation prior to receiving anti-cancer therapy. * Has HCC with intermediate, high or very high risk of recurrence. * Has hepatic only HCC (disease confined to the liver only), defined by no extra-hepatic lesions greater than 1 cm in size. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Patient with past or ongoing hepatitis C virus (HCV) infection will be eligible if the patient has completed HCV treatment at least 1 month prior to Day 1. * Patient with controlled hepatitis B will be eligible if the patient meets the following criteria: 1. Antiviral therapy for hepatitis B virus (HBV) must be given for at least 4 weeks, and HBV viral load must be less than 500 IU/mL prior to treatment. Patients on active HBV therapy with viral loads under 500 IU/mL should stay on the same therapy throughout study treatment. 2. Patients who are hepatitis B core antibody (anti-HBc) positive, negative for HBsAg, and negative or positive for anti- HBs, and who have an HBV viral load under 500 IU/mL do not require HBV anti-viral prophylaxis. * Patients who are not exposed to unreasonable risks by continued use of the investigational agent in spite of progression of disease. Such criteria may include the following: 1. Absence of symptoms and signs indicating clinically significant progression of disease. 2. No decline in performance status, as measured by ECOG or Karnofsky or both. 3. Absence of symptomatic rapid disease progression requiring urgent medical intervention. 4. Ensure that patients are reconsenting to treatment with the Informed Consent clearly stating that retreatment is not standard of care. * Has adequate organ function as specified in the Adequate Organ Function Laboratory Values Table. Specimens must be collected within 14 days prior to Day 1. 1. Hematological: Absolute neutrophil count ≥1500/µL or ANC of ≤1500/µL if there is a stable medical history of neutropenia per provider discretion; Platelets ≥40,000/µL; Hemoglobin ≥8.0 g/dL. 2. Renal: Creatinine OR measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × ULN OR GFR ≥30 mL/min for patients with creatinine levels \>1.5 × institutional ULN 3. Hepatic: Total bilirubin ≤2 mg/dL OR direct bilirubin ≤ULN for patients with total bilirubin levels \>2 mg/dL; AST (SGOT) and ALT (SGPT) ≤5 × ULN; Albumin (c) \>2.6 g/dL 4. Coagulation: International normalized ratio (INR) OR prothrombin time (PT) ≤1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT is within therapeutic range of intended use of anticoagulants Retreatment Inclusion Criteria: * Patients receiving retreatment with IP-001 following intrahepatic recurrence must satisfy all of the following: * Radiographic recurrence remains amenable to curative-intent thermal ablation. * No symptomatic rapid disease progression requiring urgent systemic therapy or palliative intervention. * ECOG performance status remains 0-2. * No evidence of clinically significant hepatic decompensation. * No extrahepatic disease that would preclude additional local therapy. * The Investigator determines that additional thermal ablation remains clinically appropriate. * The patient continues to satisfy protocol safety requirements.
Exclusion criteria
* Known allergic reaction to shellfish, crabs, crustacean, or any trial components used in trial treatment. * Has an active infection requiring systemic therapy. * Has a diagnosis of immunodeficiency or currently receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent), or any other form of immunosuppressive therapy within 7 days prior to treatment day (Day 1), or has plans to start treatment including \>10 mg daily of prednisone equivalent or any immunotherapy. * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents or immunosuppressive drugs). NOTE: replacement therapy (e.g., thyroxine or insulin) is not considered a form of systemic treatment and is allowed. * Has had an allogeneic tissue/solid organ transplant, or eligible for a liver transplant and/or on the liver transplantation waiting list. * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, active tuberculosis, or idiopathic pneumonitis. * Has received local therapy to the liver, ablation other than microwave ablation (i.e., alcohol ablation, transcatheter chemoembolization, transcatheter embolization, hepatic arterial infusion, local radiation/Stereotactic Body Radiation Therapy or radioembolization) less than 3 months prior to treatment. * Is receiving any of the following prohibited concomitant therapies less than 21 days from treatment or 5 drug elimination half-lives, whichever is shorter, prior to randomization: 1. Antineoplastic systemic chemotherapy or biological therapy. 2. Immunotherapy not specified in this protocol. 3. Systemic glucocorticoids for any purpose other than to modulate symptoms from an adverse event (AE) that is suspected to have an immunologic etiology. Inhaled or topical steroids are allowed, and systemic steroids at doses ≤10 mg/day prednisone or equivalent are allowed. Exception: steroids may be used for premedication prior to imaging. * Has received a live vaccine within 28 days prior to treatment Day 1. Retreatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence Free Survival | From Date of Randomization until date of documented progression, assessed up to 60 months | Radiological assessments (Triphasic CT or MRI) of the chest, abdomen and pelvis will occur every 12 weeks for the first 2 years, then every 24 weeks thereafter. Recurrence will be determined by the investigator's radiological review per RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cancer Free Survival | Months 12 and 24 | Participants will be followed every 12 weeks from treatment Day 1 for the first 2 years, and every 24 weeks thereafter until disease related death. |
| Overall Survival | Months 12 and 24 | Participants will be followed every 12 weeks from treatment Day 1 for the first 2 years, and every 24 weeks thereafter until death of any cause. |
| Overall Survival Rate | Months 12 and 24 | Proportion of participants who have not experienced death from treatment Day 1 at 12 and 24 months after treatment. |
| Recurrence Free Survival Rate | Months 12 and 24 | Assessed from treatment Day 1 to documentation of disease recurrence or extrahepatic) or death, whichever occurs first. |
| Time to Intrahepatic Tumor Recurrence | From Date of Randomization until date of documented progression, assessed up to 60 months | Radiological assessments (Triphasic CT or MRI) of the chest, abdomen and pelvis will occur every 12 weeks for the first 2 years, then every 24 weeks thereafter. Recurrence will be determined by the investigator's radiological review per RECIST v1.1 |
| Time to Extrahepatic Tumor Recurrence | From Date of Randomization until date of documented progression, assessed up to 60 months | Radiological assessments (Triphasic CT or MRI) of the chest, abdomen and pelvis will occur every 12 weeks for the first 2 years, then every 24 weeks thereafter. Recurrence will be determined by the investigator's radiological review per RECIST v1.1 |
Countries
United States
Contacts
CONTACTRobert Martin, MD, PhD
PRINCIPAL_INVESTIGATORRobert CG Martin, MD, PhD
University of Louisville
Outcome results
None listed